Trial Profile
A Phase II Randomised Efficacy and Safety Study of Vandetanib (ZD 6474) in Combination With Bicalutamide Versus Bicalutamide Alone in Patients With Chemotherapy-Naive Hormone-Refractory Prostate Cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Vandetanib (Primary) ; Bicalutamide
- Indications Prostate cancer
- Focus Therapeutic Use
- 28 Mar 2014 Primary endpoint 'Prostate-specific-antigen-response-rate' has not been met.
- 28 Mar 2014 Results published in the Investigational New Drugs.
- 12 Jun 2009 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.